A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin or Rapid Acting Insulin in Patients With Type 2 Diabetes.
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2014
At a glance
- Drugs Pramlintide (Primary) ; Insulin aspart; Insulin detemir; Insulin glargine; Insulin glulisine; Insulin lispro; Insulins
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms INSTEAD
- Sponsors Amylin Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 03 Mar 2010 Treatment satisfaction and quality-of-life effects published in Current Medical Research and Opinion.
- 29 Sep 2009 Results have been presented at EASD 2009.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History